<p>波士顿科学（NYSE:BSX - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 从 “买入” 评级下调至 “持有” 评级。</p>
<ul>
<li>注意死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
<p>BSX 曾受到多份研究报告的关注。高盛集团在周四的报告中将波士顿科学的目标价设定为 99.00 美元。瑞银集团将波士顿科学的目标价从 140.00 美元下调至 120.00 美元，并在周四的研究报告中给予该公司 “买入” 评级。瑞穗证券将波士顿科学的目标价从 140.00 美元下调至 115.00 美元，并在周四的研究报告中给予该股票 “跑赢大盘” 评级。摩根大通将波士顿科学的目标价从 135.00 美元下调至 100.00 美元，并在周四的报告中给予该公司 “增持” 评级。最后，桑福德·C·伯恩斯坦在周五的报告中重申了 “跑赢大盘” 评级，并对波士顿科学的股票设定了 112.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，二十位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 109.43 美元。</p>
<p>获取 <strong>波士顿科学</strong> 的提醒：</p>
<p><strong>查看我们关于波士顿科学的最新研究报告</strong></p>
<h2>波士顿科学股票表现</h2>
<ul>
<li>3 只利用人工智能推动增长的医疗股票</li>
</ul>
<p>周五，NYSE BSX 的开盘价为 76.24 美元。该公司的市值为 1130.2 亿美元，市盈率为 39.30，市盈增长比率为 1.37，贝塔值为 0.67。该公司的速动比率为 0.96，流动比率为 1.51，债务股本比率为 0.47。波士顿科学的 50 日移动平均线为 93.39 美元，200 日移动平均线为 98.79 美元。波士顿科学的 12 个月低点为 74.86 美元，12 个月高点为 109.50 美元。</p>
<p>波士顿科学（NYSE:BSX - 获取免费报告）最近于 2 月 4 日星期三发布了季度财报。这家医疗设备提供商报告该季度每股收益为 0.80 美元，超出分析师共识预期的 0.78 美元，超出幅度为 0.02 美元。波士顿科学的净利润率为 14.44%，股本回报率为 19.96%。该季度的营业收入为 52.9 亿美元，而分析师预期为 52.9 亿美元。在去年同期，该公司的每股收益为 0.70 美元。与去年同期相比，波士顿科学的收入增长了 15.9%。波士顿科学将其 2026 年第一季度的指导目标设定为 0.780-0.800 每股收益，并将其 2026 财年的指导目标设定为 3.430-3.490 每股收益。卖方分析师预测波士顿科学在当前年度的每股收益将达到 2.85 美元。</p>
<h2>内部人士下注</h2>
<ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
<p>在相关消息中，首席执行官迈克尔·F·马霍尼于 2 月 2 日星期一出售了公司 160,901 股股票。股票的平均售价为 93.49 美元，总价值为 15,042,634.49 美元。交易完成后，首席执行官直接持有公司 1,411,735 股股票，估值约为 131,983,105.15 美元。此次交易使其持股减少了 10.23%。该出售在与证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，执行副总裁亚瑟·C·巴彻于 12 月 1 日星期一出售了 17,313 股股票。股票的平均售价为 101.55 美元，总价值为 1,758,135.15 美元。交易完成后，执行副总裁直接持有公司 23,600 股股票，估值约为 2,396,580 美元。这代表其持股减少了 42.32%。该出售的 SEC 文件提供了更多信息。内部人士持有公司 0.50% 的股票。</p>
<h2>波士顿科学的机构交易</h2>
<p>最近，一些对冲基金买入和卖出了该公司的股票。Steph &amp; Co.在第三季度购买了波士顿科学的新股份，价值约为 25,000 美元。Financial Consulate Inc.在第三季度购买了波士顿科学的新头寸，价值 25,000 美元。Murphy &amp; Mullick Capital Management Corp 在第三季度将其在波士顿科学的持股增加了 200.0%。Murphy &amp; Mullick Capital Management Corp 现在持有该医疗设备提供商的 255 股股票，价值 25,000 美元，此前在该期间内又购买了 170 股。FWL Investment Management LLC 在第二季度购买了波士顿科学的新股份，价值 26,000 美元。最后，United Community Bank 在第三季度将其在波士顿科学的持股增加了 115.7%。United Community Bank 现在持有该医疗设备提供商的 274 股股票，价值 27,000 美元，此前在该期间内又购买了 147 股。机构投资者持有公司 89.07% 的股票。</p>
<h2>关于波士顿科学的热门头条</h2>
<p>以下是本周影响波士顿科学的主要新闻故事：</p>
<ul>
<li>积极情绪：第四季度业绩超预期但前景混合——波士顿科学报告了强于预期的第四季度业绩（收入增长和每股收益超出预期），显示出持续的收入增长势头，支持长期增长故事。第四季度业绩和演示</li>
<li>积极情绪：一些分析师仍将 BSX 评级为买入/增持，目标价中高——多家机构给予了积极评级（摩根士丹利设定了 118 美元的目标价；其他机构维持 “跑赢大盘/增持”），表明尽管短期谨慎，分析师对长期上涨的信心依然存在。摩根士丹利目标价说明</li>
<li>中性情绪：董事会变动公告——波士顿科学披露了一名长期董事的离职计划；治理变动显著，但目前未被标记为对短期运营有重大影响。董事会董事离职</li>
<li>中性情绪：期权和交易量异常活跃——在抛售期间，期权和股票交易量激增，增加了波动性，使短期价格波动更加剧烈（可能放大下跌和上涨的幅度）。期权活动</li>
<li>消极情绪：谨慎的 2026 年指引和疲软的电生理销售导致剧烈抛售——管理层的保守收入/增长指引和关键领域的表现疲软促使高交易量的清算，抹去了近期的涨幅。指引和领域疲软</li>
<li>消极情绪：多项证券欺诈调查公告——多家律师事务所已对波士顿科学在季度/指引方面的披露展开调查，增加了法律和声誉风险。Howard G. Smith 调查 Frank R. Cruz 调查</li>
<li>消极情绪：内部人士抛售和新低——首席执行官的股票出售和关于内部人士抛售的头条新闻与股票达到 12 个月低点同时发生，这可能削弱投资者信心，即使基本面表现混合。首席执行官股票出售说明 12 个月低点报告</li>
<li>消极情绪：分析师普遍下调目标价——多家机构在第四季度/指引后下调了 12 个月目标价，增加了短期下行压力，即使评级仍然积极。分析师下调汇总</li>
</ul>
<h2>关于波士顿科学</h2>
<p>(获取免费报告)</p>
<p>波士顿科学公司 NYSE: BSX 是一家全球医疗设备公司，开发、制造和销售广泛的产品组合，用于微创医疗程序。公司成立于 1979 年，由约翰·阿贝尔和彼得·尼古拉斯创立，总部位于马萨诸塞州马尔堡，专注于使医生能够治疗各种心血管、消化、泌尿、肺部和慢性疼痛疾病的技术，而无需进行开放手术。</p>
<p>波士顿科学的活动涵盖产品开发、临床研究、监管事务和商业销售。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过波士顿科学</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在波士顿科学吗？</h2>
<p>在考虑波士顿科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而波士顿科学并不在名单上。</p>
<p>虽然波士顿科学目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普健康医疗设备 ETF - SPDR

波士顿科学

美国医药设备 ETF - iShares

<p>华尔街禅在最近的一份报告中将波士顿科学（NYSE:BSX）的评级从 “买入” 下调至 “持有”。其他分析师的意见各不相同，高盛设定的目标价为 99 美元，瑞银将其目标价从 140 美元下调至 120 美元，瑞穗则将目标价从 140 美元下调至 115 美元。该股票开盘价为 76.24 美元，市值为 1130.2 亿美元。波士顿科学报告了上一季度每股收益为 0.80 美元，超出预期，并为 2026 年第一季度设定了 0.780-0.800 美元的指导目标</p>

<p>Boston Scientific (NYSE:BSX - Get Free Report) was downgraded by Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Saturday.</p>
<div class="lb-trans"><p>波士顿科学（NYSE:BSX - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 从 “买入” 评级下调至 “持有” 评级。</p>
</div><ul>
<li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>注意死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
</div><p>BSX has been the subject of a number of other research reports. The Goldman Sachs Group set a $99.00 target price on Boston Scientific in a report on Thursday. UBS Group reduced their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday. Mizuho lowered their target price on shares of Boston Scientific from $140.00 to $115.00 and set an &#34;outperform&#34; rating on the stock in a research note on Thursday. JPMorgan Chase &amp; Co. cut their price target on shares of Boston Scientific from $135.00 to $100.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday. Finally, Sanford C. Bernstein reaffirmed an &#34;outperform&#34; rating and issued a $112.00 price target on shares of Boston Scientific in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $109.43.</p>
<div class="lb-trans"><p>BSX 曾受到多份研究报告的关注。高盛集团在周四的报告中将波士顿科学的目标价设定为 99.00 美元。瑞银集团将波士顿科学的目标价从 140.00 美元下调至 120.00 美元，并在周四的研究报告中给予该公司 “买入” 评级。瑞穗证券将波士顿科学的目标价从 140.00 美元下调至 115.00 美元，并在周四的研究报告中给予该股票 “跑赢大盘” 评级。摩根大通将波士顿科学的目标价从 135.00 美元下调至 100.00 美元，并在周四的报告中给予该公司 “增持” 评级。最后，桑福德·C·伯恩斯坦在周五的报告中重申了 “跑赢大盘” 评级，并对波士顿科学的股票设定了 112.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，二十位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 109.43 美元。</p>
</div><p>Get <strong>Boston Scientific</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>波士顿科学</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Research Report on Boston Scientific</strong></p>
<div class="lb-trans"><p><strong>查看我们关于波士顿科学的最新研究报告</strong></p>
</div><h2>Boston Scientific Stock Performance</h2>
<div class="lb-trans"><h2>波士顿科学股票表现</h2>
</div><ul>
<li>3 Healthcare Stocks Using AI to Drive Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只利用人工智能推动增长的医疗股票</li>
</ul>
</div><p>NYSE BSX opened at $76.24 on Friday. The firm has a market cap of $113.02 billion, a P/E ratio of 39.30, a price-to-earnings-growth ratio of 1.37 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company's 50 day moving average is $93.39 and its 200-day moving average is $98.79. Boston Scientific has a 12-month low of $74.86 and a 12-month high of $109.50.</p>
<div class="lb-trans"><p>周五，NYSE BSX 的开盘价为 76.24 美元。该公司的市值为 1130.2 亿美元，市盈率为 39.30，市盈增长比率为 1.37，贝塔值为 0.67。该公司的速动比率为 0.96，流动比率为 1.51，债务股本比率为 0.47。波士顿科学的 50 日移动平均线为 93.39 美元，200 日移动平均线为 98.79 美元。波士顿科学的 12 个月低点为 74.86 美元，12 个月高点为 109.50 美元。</p>
</div><p>Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the business earned $0.70 EPS. Boston Scientific's revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts predict that Boston Scientific will post 2.85 earnings per share for the current year.</p>
<div class="lb-trans"><p>波士顿科学（NYSE:BSX - 获取免费报告）最近于 2 月 4 日星期三发布了季度财报。这家医疗设备提供商报告该季度每股收益为 0.80 美元，超出分析师共识预期的 0.78 美元，超出幅度为 0.02 美元。波士顿科学的净利润率为 14.44%，股本回报率为 19.96%。该季度的营业收入为 52.9 亿美元，而分析师预期为 52.9 亿美元。在去年同期，该公司的每股收益为 0.70 美元。与去年同期相比，波士顿科学的收入增长了 15.9%。波士顿科学将其 2026 年第一季度的指导目标设定为 0.780-0.800 每股收益，并将其 2026 财年的指导目标设定为 3.430-3.490 每股收益。卖方分析师预测波士顿科学在当前年度的每股收益将达到 2.85 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>3 Biotech Catalysts Present Major Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
</div><p>In related news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.50% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官迈克尔·F·马霍尼于 2 月 2 日星期一出售了公司 160,901 股股票。股票的平均售价为 93.49 美元，总价值为 15,042,634.49 美元。交易完成后，首席执行官直接持有公司 1,411,735 股股票，估值约为 131,983,105.15 美元。此次交易使其持股减少了 10.23%。该出售在与证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，执行副总裁亚瑟·C·巴彻于 12 月 1 日星期一出售了 17,313 股股票。股票的平均售价为 101.55 美元，总价值为 1,758,135.15 美元。交易完成后，执行副总裁直接持有公司 23,600 股股票，估值约为 2,396,580 美元。这代表其持股减少了 42.32%。该出售的 SEC 文件提供了更多信息。内部人士持有公司 0.50% 的股票。</p>
</div><h2>Institutional Trading of Boston Scientific</h2>
<div class="lb-trans"><h2>波士顿科学的机构交易</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the company. Steph &amp; Co. bought a new stake in shares of Boston Scientific in the 3rd quarter worth approximately $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the 3rd quarter valued at $25,000. Murphy &amp; Mullick Capital Management Corp raised its position in Boston Scientific by 200.0% in the 3rd quarter. Murphy &amp; Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter worth $26,000. Finally, United Community Bank boosted its position in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 147 shares during the period. Institutional investors own 89.07% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些对冲基金买入和卖出了该公司的股票。Steph &amp; Co.在第三季度购买了波士顿科学的新股份，价值约为 25,000 美元。Financial Consulate Inc.在第三季度购买了波士顿科学的新头寸，价值 25,000 美元。Murphy &amp; Mullick Capital Management Corp 在第三季度将其在波士顿科学的持股增加了 200.0%。Murphy &amp; Mullick Capital Management Corp 现在持有该医疗设备提供商的 255 股股票，价值 25,000 美元，此前在该期间内又购买了 170 股。FWL Investment Management LLC 在第二季度购买了波士顿科学的新股份，价值 26,000 美元。最后，United Community Bank 在第三季度将其在波士顿科学的持股增加了 115.7%。United Community Bank 现在持有该医疗设备提供商的 274 股股票，价值 27,000 美元，此前在该期间内又购买了 147 股。机构投资者持有公司 89.07% 的股票。</p>
</div><h2>Trending Headlines about Boston Scientific</h2>
<div class="lb-trans"><h2>关于波士顿科学的热门头条</h2>
</div><p>Here are the key news stories impacting Boston Scientific this week:</p>
<div class="lb-trans"><p>以下是本周影响波士顿科学的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation</li>
<li>Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note</li>
<li>Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure</li>
<li>Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity</li>
<li>Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness</li>
<li>Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigationFrank R. Cruz investigation</li>
<li>Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note12-month low report</li>
<li>Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第四季度业绩超预期但前景混合——波士顿科学报告了强于预期的第四季度业绩（收入增长和每股收益超出预期），显示出持续的收入增长势头，支持长期增长故事。第四季度业绩和演示</li>
<li>积极情绪：一些分析师仍将 BSX 评级为买入/增持，目标价中高——多家机构给予了积极评级（摩根士丹利设定了 118 美元的目标价；其他机构维持 “跑赢大盘/增持”），表明尽管短期谨慎，分析师对长期上涨的信心依然存在。摩根士丹利目标价说明</li>
<li>中性情绪：董事会变动公告——波士顿科学披露了一名长期董事的离职计划；治理变动显著，但目前未被标记为对短期运营有重大影响。董事会董事离职</li>
<li>中性情绪：期权和交易量异常活跃——在抛售期间，期权和股票交易量激增，增加了波动性，使短期价格波动更加剧烈（可能放大下跌和上涨的幅度）。期权活动</li>
<li>消极情绪：谨慎的 2026 年指引和疲软的电生理销售导致剧烈抛售——管理层的保守收入/增长指引和关键领域的表现疲软促使高交易量的清算，抹去了近期的涨幅。指引和领域疲软</li>
<li>消极情绪：多项证券欺诈调查公告——多家律师事务所已对波士顿科学在季度/指引方面的披露展开调查，增加了法律和声誉风险。Howard G. Smith 调查 Frank R. Cruz 调查</li>
<li>消极情绪：内部人士抛售和新低——首席执行官的股票出售和关于内部人士抛售的头条新闻与股票达到 12 个月低点同时发生，这可能削弱投资者信心，即使基本面表现混合。首席执行官股票出售说明 12 个月低点报告</li>
<li>消极情绪：分析师普遍下调目标价——多家机构在第四季度/指引后下调了 12 个月目标价，增加了短期下行压力，即使评级仍然积极。分析师下调汇总</li>
</ul>
</div><h2>About Boston Scientific</h2>
<div class="lb-trans"><h2>关于波士顿科学</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.</p>
<div class="lb-trans"><p>波士顿科学公司 NYSE: BSX 是一家全球医疗设备公司，开发、制造和销售广泛的产品组合，用于微创医疗程序。公司成立于 1979 年，由约翰·阿贝尔和彼得·尼古拉斯创立，总部位于马萨诸塞州马尔堡，专注于使医生能够治疗各种心血管、消化、泌尿、肺部和慢性疼痛疾病的技术，而无需进行开放手术。</p>
</div><p>Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.</p>
<div class="lb-trans"><p>波士顿科学的活动涵盖产品开发、临床研究、监管事务和商业销售。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Boston Scientific</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过波士顿科学</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=BSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在波士顿科学吗？</h2>
</div><p>Before you consider Boston Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑波士顿科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而波士顿科学并不在名单上。</p>
</div><p>While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然波士顿科学目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

波士顿科学（NYSE:BSX）在 Wall Street Zen 被下调至 “持有” 评级